Vyvanse

ADHD.

Adult & ped patient ≥6 yr Initially 30 mg once daily in the morning, may be adjusted in increments of 10 mg or 20 mg at approx wkly intervals. Max dose: 70 mg once daily. Patient w/ severe renal impairment (GFR 15 to <30 mL/min/1.73 m²) Max dose: 50 mg once daily. Patient w/ ESRD (GFR <15 mL/min/1.73 m²) Max dose: 30 mg once daily.

May be taken with or without food: Swallow whole. Alternatively, open cap, empty & mix entire contents w/ yogurt, water, or orange juice until completely dispersed, then consume entire mixt immediately. Do not divide a single dose.

Hypersensitivity to amphetamine products. Patients taking MAOIs or w/in 14 days of stopping MAOIs (including linezolid or IV methylene blue).

Not indicated or recommended for wt loss. Avoid afternoon doses because of the potential for insomnia. High potential for abuse, misuse, & addiction; assess risk before prescribing & frequently monitor for signs & symptoms throughout treatment. Assess for the presence of cardiac disease prior to initiating treatment. Avoid use in patients w/ known structural cardiac abnormalities, cardiomyopathy, serious cardiac arrhythmia, CAD, or other serious cardiac disease. Monitor for potential tachycardia & HTN. May exacerbate symptoms of behavior disturbance & thought disorder in patients w/ pre-existing psychotic disorder. May induce a manic or mixed episode in patients w/ bipolar disorder. May cause psychotic or manic symptoms in patients w/o prior history of psychotic illness or mania. Associated w/ wt loss & slowing of growth rate in ped patients; closely monitor growth (wt & height). Associated w/ peripheral vasculopathy, including Raynaud's phenomenon; carefully observe for digital changes during treatment. Associated w/ onset or exacerbation of motor & verbal tics & worsening of Tourette's syndrome; assess family history & clinically evaluate patients before initiating treatment. Post-marketing reports of suicide-related events; monitor for signs of suicide-related behavior. Immediately discontinue treatment w/ Vyvanse & any concomitant serotonergic agents if symptoms of serotonin syndrome occur. Reduced clearance in patients w/ severe renal impairment or ESRD. Not dialyzable. May decrease placental perfusion. Increased risk of premature delivery & low birth wt in infants born to amphetamine-dependent mothers; monitor for w/drawal symptoms eg, feeding difficulties, irritability, agitation, & excessive drowsiness. Breastfeeding is not recommended during treatment. Not approved for use in ped patients <6 yr.

Anorexia, anxiety, decreased appetite/wt, diarrhea, dizziness, dry mouth, irritability, insomnia, nausea, upper abdominal pain, vomiting.

Slowed metabolism & increased effect w/ MAOIs. Increased risk of serotonin syndrome w/ serotonergic drugs & CYP2D6 inhibitors. Increased blood levels & potentiated action w/ urinary alkalinizing agents. Decreased blood levels & efficacy w/ urinary acidifying agents. Increased brain conc & potentiated CV effects w/ TCAs.

Other CNS Drugs & Agents for ADHD

N06BA12 - lisdexamfetamine ; Belongs to the class of centrally-acting sympathomimetics. Used as CNS stimulant.

P₁S₁S₃